Keywords: roche, mabthera, cleared, eu, first-line, use, non-hodgkin
Roche's MabThera cleared in EU for first-line use in non-Hodgkin's lymphoma
Article | 16 August 2004
The European Commission has approved the first-line use of Roche'sMabThera (Rituxan; rituximab) for the treatment of indolent non-Hodgkin's lymphoma in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
